PO.IM02.05 · 免疫学

Tumor cell CEBPB expression contributes to T cell-mediated immune evasion of microsatellite stable colorectal cancer

海报缩略图:Tumor cell CEBPB expression contributes to T cell-mediated immune evasion of microsatellite stable colorectal cancer
编号 7005 展板 17 时间 4/22 09:00–12:00 区域 Section 9 主讲 Hye Jeong Yun, PhD
分会场 Tumor-induced Immune Suppression
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Hye Jeong Yun1, Chan Ho Park2, Dahye Yun1, Hye-Ri Shin3, Naeun Park1, Changhee Park4, Jeong Dong Lee1, Kiyeon Kim2, Heejun Shim2, Hyejin Sim1, Se Min Kim1, Min Jung Kim5, Ji Won Park5, Seung-Bum Ryoo5, Yoojoo Lim6, Seung-Yong Jeong5, Kyu Joo Park5, Tae-You Kim4, Junil Kim2, Jae-Kyung Won3, Sae-Won Han4

1Cancer Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of,2Department of Bioinformatics, Soongsil University, Seoul, Korea, Republic of,3Department of Pathology, Seoul National University Hospital, Seoul, Korea, Republic of,4Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of,5Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of,6Lunit, Seoul, Korea, Republic of

摘要 Abstract

Background: Microsatellite stable (MSS) colorectal cancer (CRC), which accounts for approximately 80-85% of all colorectal cancer cases, exhibits a poor response to immune checkpoint inhibitors. Tumor protein 53 ( TP53 ) mutations are frequently observed in colorectal cancer and may contribute to tumor-driven immunosuppression. In this study, we aimed to investigate the immunosuppressive mechanisms associated with TP53 mutations in MSS CRC. Methods: We performed single-cell RNA sequencing (scRNA-seq) on tumor samples from 30 CRC patients and Trp53 - knockout (KO) CT26 tumors in syngeneic mice to profile the tumor microenvironment and analyze tumor cell gene expression profiles based on TP53 mutation status. We identified CCAAT enhancer-binding protein beta ( CEBPB ) as a potential immunosuppressive factor associated with TP53 -mutant CRC. To demonstrate the role of CEBPB in T cell immunosuppression, we analyzed T cell-tumor cell co-cultures and CEBPB -overexpressing (oe) tumor-injected syngeneic mouse models by flow cytometry. Results: scRNA-seq analysis of 30 CRCs revealed increased proportions of CD4 + T cell subsets, including Treg, Th17, and Tcm cells, in TP53 mutant tumors. Immune activation pathways, such as the immune system and interferon-gamma response, were down-regulated in T cells compared to TP53 wild-type tumors, suggesting that TP53 mutations might contribute to immune evasion by negatively affecting T cells. scRNA-seq analysis of Trp53 -KO CT26 tumors identified CEBPB as notably upregulated, and we confirmed that loss of Trp53 WT led to increased CEBPB mRNA expression and protein stability in CRC cell lines. CEBPB expression was associated with reduced CD4 + T cell infiltration and positively correlated with cytotoxic T lymphocyte-associated protein 4 ( CTLA4 ) expression in regulatory T cells (Treg) and exhausted T cells (Tex). CEBPB -oe CT26 tumors in syngeneic mice showed reduced CD4 + T cell infiltration and upregulation of CTLA-4 expression on CD4 + T cells in vivo . Consistently, spleen T co-cultured with CEBPB -overexpressing CT26 cells showed increased CTLA-4 expression and decreased proliferation of CD4⁺ T cells. Conclusion: Tumor cell CEBPB expression, upregulated by TP53 mutation, may mediate T cell-mediated immunosuppression and is considered as potential therapeutic target for regulating immune evasion in MSS CRC.
利益披露 Disclosure
H. Yun, None.. C. Park, None.. D. Yun, None.. H. Shin, None.. N. Park, None.. C. Park, None.. J. Lee, None.. K. Kim, None.. H. Shim, None.. H. Sim, None.. S. Kim, None.. M. Kim, None.. J. Park, None.. S. Ryoo, None. Y. Lim, Lunit Employment. S. Jeong, None.. K. Park, None.. T. Kim, None.. J. Kim, None.. J. Won, None. S. Han, Arcus Biosciences ). AstraZeneca ). BeyondBio ). Eli Lilly and Company ). GC Biopharma ). Genentech ). Hanmi pharmaceutical ). IMBdx ). Janssen Pharmaceuticals ). Jeil Pharmaceutical Co. ). Jiangsu Hengrui Pharmaceuticals Co. ). Leap Therapeutics ). Loxo Oncology, Inc. ). MedImmune, LLC ). MSD ). Roche ). Seagen Inc. ). Turnstone Biologics ). Ono Pharmaceutical ). boryung biopharma ).

在会议检索中打开